

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Imtiaz Chaudry

Title: Inhalable Formulations For Treating Pulmonary Hypertension and Methods of Using Same

Appl. No.: TBA

Filing Date: TBA

Examiner: TBA

Art Unit: TBA

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on modified Form PTO-1449 is a listing of documents known to the undersigned in order to comply with applicant's duty of disclosure pursuant to 37 CFR 1.56. Copies of each listed document are enclosed herein.

The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b).

Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The instant Information Disclosure Statement is being filed before the mailing date of any action on the merits. Accordingly, pursuant to 37 CFR §1.97, no certification, petition and fee are required.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of form PTO-1449 be returned in accordance with MPEP §609.

Respectfully submitted,

Date: 6/26/03

By:



Thomas J. Parker  
Reg. No.: 42,042  
Coudert Brothers LLP  
1114 Avenue of the Americas  
New York, NY 10036

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 0040964-0002		SERIAL NO. TBA		
				FILING TBA	GROUP TBA			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5,376,666	12/27/1994	Duncia	514	303	11/30/1992	
		6,559,313	05/06/2003	Myers, et al.	546	279.1	03/22/2002	
		6,174,906	01/16/2001	Elliot, et al.	514	365	10/01/1999	
		6,197,762	03/06/2001	Garvey, et al.	514	174	09/18/1998	
		5,968,911	10/19/1999	Lawson, et al.	514	46	02/18/1997	
		5,873,359	02/23/1999	Zapol, et al.	128	203.12	12/09/1994	
		20020115655	08/22/2002	Mehanna, Ahmed S.	514	217.03	10/31/2001	
		20010031738	10/18/2001	Schwarz, Margaret A.	514	44	12/15/2000	
		20030078190	04/24/2003	Weinberg, Marc S.	514	1	05/24/2002	
		20020132787	09/19/2002	Eljamal, Mohammed, et al.	514	44	09/19/2002	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
		Canadian Journal of Anesthesia, Volume 49, Number 9, November 2002, Excellence in clinically-related research and knowledge, Cardiothoracic Anesthesia, Respiration and Airway, Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass, Kassiani Theodoraki MD DEAA, Panagiota Rellia MD, Apostolos Thanopoulos MD, Loukas Tsourelis MD, Dimitrios Zarkalis MD, Petros Syrakis MD, Theophani Antoniou MD						
		The England Journal of Medicine, Volume 327, July 9, 1992, Number 2, The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension, Stuart Rich, MD, Elizabeth Kaufman, RN, and Paul S. Levy, Sc.D						
EXAMINER				DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY DOCKET NO. 0040964-0002		SERIAL NO. TBA		
			FILING TBA		GROUP TBA		
			U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
		American College of Physicians, Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension, Annals of Internal Medicine 1 May 1996, 124:820-824. Horst Olszewski, MD; Dieter Walmrath, MD; Ralph Schermuly, PhD, H. Ardesir Ghofrani, MD; Friedrich Grimminger, MD, HPhD; and Werner Seeger, MD					
		Pulmonary Hypertension Treatment, Iloprost Inhaled Prostacyclin, <a href="http://www.pulmonary-hypertension-treatments.com/ilo-prost.html">www.pulmonary-hypertension-treatments.com/ilo-prost.html</a> .					
EXAMINER			DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY DOCKET NO. 0040964-0002		SERIAL NO. TBA			
			FILING TBA	GROUP		TBA		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
		The Columbia Encyclopedia, Sixth Edition. 2001 beta-blocker <a href="http://www.bartleby.com/65/be/beta-b.html">www.bartleby.com/65/be/beta-b.html</a>						
		Postgraduate Medine, Beta blockers of CHF, Adrenergic blockade dramatically reduces morbidity and mortality, Ravi K. Garg, MD; Matthew J. Sorrentino, MD, Vol. 109/No. 3/ March 2001/ Postgraduate Medicine						
EXAMINER			DATE CONSIDERED					
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								



<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 0040964-0002		SERIAL NO. TBA		
				FILING TBA		GROUP TBA		
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
			<a href="http://www.sunderland.ac.uk/~hs0dad/profile/atenolol/what.htm">What Atenolol Is and What it Does, http://www.sunderland.ac.uk/~hs0dad/profile/atenolol/what.htm</a>					
			<a href="http://www.bartleby.com/65/ac/ACE-i.html">The Columbia Encyclopedia, Sixth Edition 2001, ACE inhibitor, http://www.bartleby.com/65/ac/ACE-i.html</a>					
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>				

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY DOCKET NO. 0040964-0002		SERIAL NO.			
			FILING	GROUP				
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
		NDI Foundation, <a href="http://www.ndif.org/Terms/prostaglandin.html">http://www.ndif.org/Terms/prostaglandin.html</a>						
		ansme.com, <a href="http://define.ansme.com/words/p/prostaglandin.html">http://define.ansme.com/words/p/prostaglandin.html</a>						
EXAMINER			DATE CONSIDERED					
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO.		SERIAL NO.		
				0040964-0002				
				FILING		GROUP		
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
			Definition for: Prostacyclin, <a href="http://www.kumc.edu/instruction/medicine/pathology/ed/keywords/kw_prostacy.html">http://www.kumc.edu/instruction/medicine/pathology/ed/keywords/kw_prostacy.html</a>					
			Medlineplus, Treprostinil (Systemic), <a href="http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500385.html">http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500385.html</a>					
EXAMINER				DATE CONSIDERED				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.